| 0.96 0.01 (1.05%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.39 | 1-year : | 1.61 |
| Resists | First : | 1.19 | Second : | 1.37 |
| Pivot price | 1.08  |
|||
| Supports | First : | 0.89 | Second : | 0.74 |
| MAs | MA(5) : | 0.98 |
MA(20) : | 1.13 |
| MA(100) : | 1.16 |
MA(250) : | 1.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.1 |
D(3) : | 8.9 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 2.28 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KRON ] has closed above bottom band by 13.9%. Bollinger Bands are 18.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.94 - 0.95 | 0.95 - 0.96 |
| Close: | 0.95 - 0.96 | 0.96 - 0.97 |
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Mon, 22 Apr 2024
Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Canada Shine On
Wed, 27 Mar 2024
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Thu, 21 Mar 2024
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results - Yahoo Finance
Thu, 07 Mar 2024
Kronos Bio Implements Workforce Reduction to Extend Financial Runway - TipRanks.com - TipRanks
Thu, 07 Mar 2024
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway - GlobeNewswire
Tue, 05 Mar 2024
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 19.5 (%) |
| Held by Institutions | 44.6 (%) |
| Shares Short | 665 (K) |
| Shares Short P.Month | 600 (K) |
| EPS | -1.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.7 |
| Profit Margin | 0 % |
| Operating Margin | -994.4 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -55.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.1 |
| EBITDA (p.s.) | -1.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -79 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.5 |
| PEG Ratio | 0 |
| Price to Book value | 0.35 |
| Price to Sales | 9.17 |
| Price to Cash Flow | -0.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|